Evidence map›Paper›PMID 40979093›Full record

ArticleJournal of clinical and translational science2025

A case series on TNF-α inhibitors for APS- induced high-risk pregnancies.

Ran An, Xiaolei Wang, Ligui Xiong, Yanqi Yang, Peiling Li

Abstract readCase Reports
In one paragraph

Article in Journal of clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ran AnDepartment of Obstetrics and Gynecology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Xiaolei WangDepartment of Immunology and Rheumatology, Cangzhou Hospital of Integrated TCM-WM Hebei, Cangzhou, Hebei, P.R. China.
Ligui XiongImmune Reproductive Clinic, Hubei Provincial Hospital of TCM Affiliated to Hubei University of Traditional Chinese Medicine, Wuhan, Hubei, P.R. China.
Yanqi YangDepartment of Obstetrics and Gynecology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China.
Peiling LiDepartment of Obstetrics and Gynecology, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China.ORCID https://orcid.org/0009-0007-2906-5130

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We deliberated a case report of seven cases to investigate whether inhibitors of tumor necrosis factor-α (TNF-) could reduce pregnancy dangers caused by antiphospholipid syndrome (APS). Patient 1 was diagnosed with NC-OAPS and Hashimoto, Patient 3 was with SN-APS and Hashimoto, Patient 2, 3, 4 were with SN-APS, Patient 5 and 6 were with OAPS, and Patient 7 was with OAPS and PCOS. Patient 4 took the longest period to report the disappearance of symptoms (7 days), followed by patients 1 and 5, and lastly, 2, 3, 6 and 7; after treatment, TNF-α decreased to varying degrees in 7 patients, among which Patient 1, 3, 6, 7 reached the ideal level (< 8.1) and Patient 5 reached the highest level (123.04); Patient 6 and 7 were ongoing pregnancies. The fetuses were born to the desired gestational age except the fetus from Patient 1. A total of 5 patients underwent cesarean delivery. The average height of the newborns was 48.20 cm and the average weight was 2.50 kg. The Apgar scores ranged between 8 and 10. The ongoing pregnancies as a limitation of the dataset. Collectively, we found that TNF-α Inhibitors could prolong gestational period.

Indexed as

Antiphospholipid syndromedangerous pregnancygestational weeksinhibitorstnf-α

Identifiers

PMID40979093
PMCPMC12444713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.